A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
Clinical trial NCT03593200 · COMPLETED
Trial details
- NCT number
- NCT03593200
- Sponsor
- Apellis Pharmaceuticals, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-08-16
- Primary completion
- 2019-10-22
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.